Antiangiogenic therapy has been successful for the treatment of solid tumors.
Several strategies have been used to target angiogenesis in prostate cancer. These strategies include blocking proangiogenic factors via monoclonal antibodies or small molecule inhibitors targeting downstream signaling effector pathways, or using agents with immune-modulatory effects. This review examines the general concepts of tumor angiogenesis and the key clinical trials that have used these agents and other novel biologics in prostate cancer. Targeting angiogenesis is still a promising treatment strategy in prostate cancer with a rational trial design and combination approach.
Written by:
Lin J, Kelly WK. Are you the author?
Department of Medical Oncology, Jefferson Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Reference: Urol Clin North Am. 2012 Nov;39(4):547-60.
doi: 10.1016/j.ucl.2012.07.010
PubMed Abstract
PMID: 23084530
UroToday.com Investigative Urology Section
